DeboraAnneRauschMD

GSK, Clinical and Medical Affairs Director

Dr. Rausch is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
8008 Route 130
Ste 120
Delran, NJ 08075
Phone+1 856-764-7997

Fax+1 856-764-1840

Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Infectious Disease, 1999 - 2001
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1995 - 1998
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1995

PubMed

26 citations
Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post ...
Alemnew F Dagnew, Debora A. Rausch, Caroline Hervé, Toufik Zahaf, Myron J. Levin
Rheumatology. 2021-03-02
In reply-Vascular Event Risk After Herpes Zoster.
Brandon J. Patterson, Debora A. Rausch, Debra E. Irwin, Barbara P. Yawn
Mayo Clinic Proceedings. 2019-08-01
21 citations
Analysis of Vascular Event Risk After Herpes Zoster From 2007 to 2014 US Insurance Claims Data
Brandon J. Patterson, Debora A. Rausch, Debra E. Irwin, Michael Liang, Songkai Yan
Mayo Clinic Proceedings. 2019-05-01

Journal Articles

Cost of Herpes Zoster and Herpes Zoster-Related Complications Among Immunocompromised Individuals
Debora A Rausch, Myron J Levin, ScienceDirect

Post Hoc Analysis of Reactogenicity Trends Between Dose 1 and Dose 2 of the Adjuvanted Recombinant Zoster Vaccine in Two Parallel Randomized TrialsApril 29th, 2020